IEX · Idex
443 filings
IEX SEC Filings
Idex - 443 total filings
IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 28, 2016
- 8-K · Feb 3, 2016
- 8-K · Feb 10, 2016
- 10-K · Feb 19, 2016
- 8-K · Feb 19, 2016
- 8-K · Mar 18, 2016
- 8-K · Apr 12, 2016
- 8-K · Apr 19, 2016
- 10-Q · Apr 25, 2016
- 8-K · Apr 25, 2016
- 8-K · Jun 15, 2016
- 8-K · Jul 19, 2016
- 8-K · Jul 25, 2016
- 8-K · Jul 28, 2016
- 10-Q · Aug 1, 2016
- 8-K · Sep 2, 2016
- 8-K · Oct 18, 2016
- 8-K · Oct 21, 2016
- 10-Q · Oct 25, 2016
- 8-K · Nov 8, 2016
- 8-K · Jan 4, 2017
- 8-K · Jan 31, 2017
- 8-K · Feb 2, 2017
- 10-K · Feb 23, 2017
- 8-K · Feb 23, 2017
- 8-K/A · Mar 8, 2017
- 8-K · Apr 20, 2017
- 8-K · Apr 25, 2017
- 10-Q · Apr 26, 2017
- 8-K · Apr 27, 2017
- 8-K · Jul 26, 2017
- 10-Q · Jul 26, 2017
- 8-K · Jul 28, 2017
- 8-K · Oct 17, 2017
- 8-K · Oct 20, 2017
- 10-Q · Oct 23, 2017
- 8-K · Jan 2, 2018
- 8-K · Jan 30, 2018
- 8-K · Feb 2, 2018
- 10-K · Feb 22, 2018
- 8-K · Apr 30, 2018
- 8-K · Apr 30, 2018
- 10-Q · Apr 30, 2018
- 8-K · May 3, 2018
- 8-K · Jul 25, 2018
- 10-Q · Jul 25, 2018
- 8-K · Jul 30, 2018
- 8-K · Oct 24, 2018
- 10-Q · Oct 24, 2018
- 8-K · Jan 30, 2019
- 10-K · Feb 28, 2019
- 10-Q · Apr 26, 2019
- 8-K · Apr 26, 2019
- 8-K · May 14, 2019
- 8-K · Jun 4, 2019
- 8-K · Jun 18, 2019
- 10-Q · Jul 26, 2019
- 8-K · Jul 26, 2019
- 10-Q · Oct 30, 2019
- 8-K · Oct 30, 2019
- 8-K · Jan 30, 2020
- 10-K · Feb 21, 2020
- 8-K · Feb 26, 2020
- 8-K · Apr 24, 2020
- 10-Q · Apr 24, 2020
- 8-K · Apr 29, 2020
- 8-K · May 13, 2020
- 10-Q · Jul 24, 2020
- 8-K · Jul 24, 2020
- 8-K · Oct 28, 2020
- 8-K · Oct 28, 2020
- 10-Q · Oct 28, 2020
- 8-K · Jan 13, 2021
- 8-K · Feb 1, 2021
- 8-K · Feb 1, 2021
- 8-K · Feb 4, 2021
- 8-K/A · Feb 10, 2021
- 10-K · Feb 25, 2021
- 8-K · Feb 26, 2021
- 8-K · Apr 28, 2021
- 8-K · Apr 28, 2021
- 10-Q · Apr 28, 2021
- 8-K · May 10, 2021
- 8-K · May 14, 2021
- 8-K · May 18, 2021
- 8-K · May 28, 2021
- 8-K · Jun 17, 2021
- 8-K · Jun 21, 2021
- 8-K · Jul 2, 2021
- 8-K · Jul 28, 2021
- 10-Q · Jul 28, 2021
- 8-K · Aug 26, 2021
- 10-Q · Oct 27, 2021
- 8-K · Oct 27, 2021
- 8-K · Feb 2, 2022
- 8-K · Feb 8, 2022
- 10-K · Feb 24, 2022
- 8-K · Feb 28, 2022
- 10-Q · Apr 27, 2022
- 8-K · Apr 27, 2022
- 8-K · May 10, 2022
- 8-K · Jun 16, 2022
- 10-Q · Jul 27, 2022
- 8-K · Jul 27, 2022
- 8-K · Sep 13, 2022
- 8-K · Sep 22, 2022
- 8-K · Oct 26, 2022
- 10-Q · Oct 26, 2022
- 8-K · Nov 2, 2022
- 8-K · Nov 17, 2022
- 8-K · Nov 18, 2022
- 8-K · Dec 16, 2022
- 8-K · Feb 1, 2023
- 10-K · Feb 23, 2023
- 10-Q · Apr 27, 2023
- 8-K · Apr 27, 2023
- 8-K · May 31, 2023
- 8-K · Jun 14, 2023
- 10-Q · Jul 27, 2023
- 8-K · Jul 27, 2023
- 8-K · Aug 30, 2023
- 8-K · Aug 30, 2023
- 8-K · Oct 25, 2023
- 8-K · Oct 26, 2023
- 10-Q · Oct 26, 2023
- 8-K · Feb 7, 2024
- 10-K · Feb 22, 2024
- 10-Q · Apr 24, 2024
- 8-K · Apr 24, 2024
- 8-K · May 8, 2024
- 8-K · Jul 23, 2024
- 8-K · Aug 1, 2024
- 10-Q · Aug 1, 2024
- 8-K · Aug 8, 2024
- 8-K · Aug 21, 2024
- 8-K · Sep 5, 2024
- 10-Q · Oct 30, 2024
- 8-K · Oct 30, 2024
- 8-K · Feb 4, 2025
- 8-K · Feb 20, 2025
- 10-K · Feb 20, 2025
- 8-K · May 1, 2025
- 10-Q · May 1, 2025
- 8-K · May 12, 2025
- 8-K · May 21, 2025
- 10-Q · Jul 30, 2025
- 8-K · Jul 30, 2025
- 8-K · Sep 18, 2025
- 8-K · Oct 29, 2025
- 10-Q · Oct 29, 2025
- 8-K · Dec 4, 2025
- 8-K · Feb 4, 2026
- 8-K · Feb 9, 2026
- 10-K · Feb 19, 2026
- 8-K · Apr 29, 2026
- 10-Q · Apr 29, 2026
- 8-K · May 8, 2026
- 8-K · Jul 29, 2026
- 10-Q · Jul 29, 2026
- 8-K · Aug 17, 2026
- 8-K · Sep 3, 2026
- 8-K · Oct 28, 2026
- 10-Q · Oct 28, 2026
Idex 8-K Report, Financial Results (Oct 28, 2026)
IDEX Corporation reported record third-quarter 2026 results, with net sales of $951.7 million, up 8% on both a reported and organic basis versus the prior year period. Reported diluted EPS attributable to IDEX was $1.95, up from $1.70, and record adjusted diluted EPS was $2.33, up from $2.03, with both reported and adjusted EPS increasing 15%. Orders were $991.2 million, up 13% on both a reported and organic basis. Gross margin rose to 45.1% from 44.5%, and Adjusted EBITDA margin rose to 27.8% from 27.3%. The Health & Science Technologies segment drove much of the growth, with net sales up 14% and organic sales up 13%, supported by AI-driven demand for data center power and semiconductor markets, as well as space and defense. Cash flow was strong, with operating cash flow of $239.5 million and free cash flow of $214.3 million, compared with $188.7 million a year earlier. The company returned $129 million to shareholders through dividends and share repurchases during the quarter, and it amended and restated its $800 million revolving credit facility to extend maturity to September 2031. Management raised full-year 2026 guidance, now projecting organic sales growth of 6.5% to 6.8%, up from 5% to 6%, and adjusted diluted EPS of $8.91 to $8.96, up from $8.70 to $8.85. The filing furnishes the earnings press release as Exhibit 99.1 under Item 2.02, and that information is not deemed filed for Section 18 purposes.
Idex Quarterly Report for Q3 Ended Sep 30, 2026
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2026 reports third-quarter net sales of $951.7 million, up 8% on both a reported and organic basis versus $878.7 million a year earlier. Reported diluted EPS attributable to IDEX was $1.95, up 15% from $1.70, and adjusted diluted EPS was $2.33, up 15% from $2.03. Operating income rose to $208.0 million from $185.8 million, and gross margin was 45.1% versus 44.5%. For the nine months, net sales were $2,759.2 million, up 8%, and diluted EPS was $5.49 versus $4.70, with the company noting that IEEPA tariff refunds contributed $0.10 to nine-month diluted EPS. Growth was led by the Health & Science Technologies segment, where Q3 net sales rose 14% and Adjusted EBITDA rose 18%, driven by AI-related demand for data center power and semiconductor markets, as well as space and defense. Fluid & Metering Technologies sales rose 3% and Fire & Safety/Diversified Products sales rose 5% in the quarter. Operating cash flow for the nine months was $543.2 million, and free cash flow was $477.3 million, compared with $427.0 million a year earlier. The company repurchased $227.0 million of shares in the nine months and paid $160.7 million in dividends. Balance sheet and liquidity remain solid. Cash and cash equivalents were $602.1 million, total borrowings were $1,759.0 million, and the company entered a second amended and restated $800 million revolving credit agreement maturing September 2031. The company stated it was in compliance with its covenants, with a leverage ratio of 1.72 to 1 and an interest coverage ratio of 14.69 to 1. Fitch affirmed its BBB+ rating in September 2026.
Idex 8-K Report, Material Agreement (Sep 3, 2026)
On September 3, 2026, IDEX Corporation entered into an amended and restated credit agreement, dated as of November 1, 2022, with Bank of America, N.A. as administrative agent, swingline lender and letter of credit issuer, together with its subsidiaries as borrowers and a group of lenders and financial institutions. The filing describes the agreement as consisting of an $800 million revolving credit facility with a final maturity date of September 3, 2031. That date extends the November 1, 2027 maturity of the original agreement, and the maturity may be further extended twice, each time by one year, under certain conditions. The facility can be used for working capital and general corporate purposes, including refinancing existing company and subsidiary debt. It includes a sublimit of up to $100 million for letters of credit and up to $50 million for same-day swingline loans. The company may request commitment increases of up to $400 million in aggregate, and may designate certain foreign subsidiaries as borrowers, in which case it must guarantee their obligations. Borrowings bear interest at an alternate base rate or Term SOFR (or applicable alternative currency rates) plus an applicable margin, which is based on the better of the company's senior unsecured long-term debt rating or its leverage ratio. Voluntary prepayments and commitment reductions are permitted without penalty, subject to break funding payments and minimum notice and amount requirements. The agreement contains customary senior unsecured covenants, including a leverage ratio tested quarterly, with an option to increase the ratio for 12 months following certain acquisitions. Negative covenants restrict liens, fundamental changes such as mergers or sales of substantially all assets, certain subsidiary dividends, materially different lines of business, and certain subsidiary debt. The agreement also includes customary events of default, subject to grace periods. The filing notes that the company and the lenders maintain other commercial and investment banking relationships. The full agreement is filed as Exhibit 10.1, with certain schedules omitted under Item 601(a)(5) of Regulation S-K.
Idex 8-K Report, Executive Changes (Aug 17, 2026)
IDEX Corporation filed a Current Report on Form 8-K dated August 17, 2026, under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). The filing reports that L. Paris Watts-Stanfield resigned from the Board of Directors effective immediately on August 13, 2026. The filing states that Ms. Watts-Stanfield's decision to resign was not the result of any disagreement with the Company on any matters relating to its operations, policies or practices. The Company and the Board thanked her for her service. In connection with the resignation, the size of the Board was reduced from ten to nine directors. This is a governance-related disclosure. The filing does not announce a replacement director, a new officer appointment, or any compensatory arrangement changes.
Idex Quarterly Report for Q2 Ended Jun 30, 2026
IDEX Corporation's second-quarter 2026 results show net sales of $920.6 million for the three months ended June 30, 2026, up from $865.4 million, and net sales of $1,807.5 million for the six months, up from $1,679.7 million. Reported net income attributable to IDEX was $143.4 million for the quarter, versus $131.6 million a year earlier, and diluted EPS was $1.93 versus $1.74. The company attributes the increase mainly to organic sales growth of 5% in both periods, driven by higher volumes in the Health & Science Technologies segment, along with favorable foreign currency and acquisition contributions. Adjusted diluted EPS attributable to IDEX was $2.32 for the quarter, up from $2.07. IEEPA tariff refunds were a significant factor this quarter. The company collected substantially all anticipated refunds in Q2 2026, which reduced cost of sales by $22.0 million, partly offset by a $14.7 million reduction in net sales from expected customer rebates. Management says the net impact contributed an $0.08 benefit to EPS. Gross margin rose to 46.3% for the quarter from 45.3%, and operating income increased to $199.9 million from $187.9 million. Balance sheet and cash flow remained solid. Cash and cash equivalents were $621.3 million, borrowings were $1,866.9 million in total, and the Revolving Facility had $529.6 million of net availability. Operating cash flow for the six months was $303.7 million, and free cash flow was $263.0 million. The company returned $77.1 million through share repurchases and $53.9 million through dividends in the quarter, and $774.7 million of repurchase authorization remained at June 30, 2026.
Idex 8-K Report, Financial Results (Jul 29, 2026)
IDEX Corporation reported second-quarter 2026 results on July 29, 2026, with record sales of $921 million, up 6% on a reported basis and 5% organically. Net sales were $920.6 million versus $865.4 million a year earlier. Reported diluted EPS was $1.93, up from $1.74, and adjusted diluted EPS was a record $2.32, up 12% from $2.07. Record orders exceeded $1 billion ("$1,071.6 million"), up 29% on a reported basis and 28% organically. Health & Science Technologies drove growth, with net sales up 14% and organic sales up 12%, driven by AI-related data center power and semiconductor demand, space and defense, and positive price. The quarter included a net benefit from IEEPA tariff refunds. The filing says these refunds contributed 150 basis points to gross margin and added $0.08 to both reported and adjusted diluted EPS, partly offset by a $14.7 million reduction in net sales from expected customer rebates tied to the refunds. Operating cash flow was $200.0 million and free cash flow was $177.0 million, up from $146.9 million. The company returned $77 million through share repurchases and paid $54 million in dividends during the quarter. Management raised its full-year 2026 guidance, now projecting organic sales growth of 5% to 6% (previously 3% to 4%) and adjusted diluted EPS of $8.70 to $8.85 (previously $8.35 to $8.55). Third-quarter guidance calls for organic sales growth of 5% to 7% and adjusted diluted EPS of $2.20 to $2.25. The filing attributes the raised outlook to strong year-to-date performance and improved second-half visibility.
Idex 8-K Report, Shareholder Vote Results (May 8, 2026)
IDEX Corporation held its Annual Meeting of Stockholders on May 6, 2026, and reported the results of three shareholder votes in this Form 8-K. Stockholders elected four Class I directors, Mark A. Beck, Carl R. Christenson, Katrina L. Helmkamp and Alejandro Quiroz Centeno, to three-year terms expiring at the 2029 annual meeting. Beck received 62,032,187 votes for and 4,324,559 against, while Quiroz Centeno received 65,577,289 for and 778,817 against. Stockholders also approved, on an advisory basis, the compensation of the company's named executive officers, with 58,071,019 affirmative votes, 7,464,627 negative votes, 829,154 abstentions and 1,305,842 broker non-votes. The proposal to ratify Deloitte & Touche LLP as the independent registered public accounting firm for 2026 received 58,038,340 affirmative votes, 9,627,072 negative votes and 5,230 abstentions. Each proposal received the affirmative vote of a majority of the shares present in person or represented by proxy and entitled to vote on the matter. The filing reports governance outcomes only. It contains no financial results, guidance or other operating information, and its single exhibit is the Inline XBRL cover page.
Idex 8-K Report, Financial Results (Apr 29, 2026)
IDEX Corporation reported first quarter 2026 results for the three months ended March 31, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K. Net sales were $886.9 million, up 9% on a reported basis and 5% organically, versus $814.3 million in the prior year period. Orders were a record $988.3 million, up 13% reported and 10% organically. GAAP diluted EPS was $1.61 (up from $1.26), and adjusted diluted EPS was $2.00 (up from $1.75, or 14%). Gross margin declined to 44.9% from 45.3%, citing unfavorable mix and pressured price/cost, partly offset by productivity and volume leverage. Health & Science Technologies drove growth, with segment organic sales up 11%, attributed to AI-driven demand for data center power and semiconductor markets as well as strength in space and defense, partially offset by lower life sciences volumes. Cash generation was softer. Operating cash flow was $103.7 million versus $105.7 million, and free cash flow was $86.0 million versus $91.4 million, reflecting the timing of customer payments and higher capital expenditures. The company returned $76 million through share repurchases and $53 million through dividends during the quarter. Total borrowings rose, with $100.0 million drawn under revolving credit facilities during the period, and long-term borrowings-net increased to $1,871.8 million from $1,820.1 million at year-end 2025. Management raised its full-year 2026 guidance, now projecting organic sales growth of 3% to 4% (up from 1% to 2%) and adjusted diluted EPS of $8.35 to $8.55 (up from $8.15 to $8.35). Second quarter 2026 guidance calls for organic sales growth of 3% to 4% and adjusted diluted EPS of $2.07 to $2.12.
Idex Quarterly Report for Q1 Ended Mar 31, 2026
IDEX Corporation reported first-quarter 2026 net sales of $886.9 million, up from $814.3 million a year earlier, with organic sales increasing 5% driven mainly by higher volumes in the Health & Science Technologies segment, particularly in AI-driven data center power and semiconductor markets, along with positive price across segments. Operating income rose to $172.4 million from $142.0 million, and diluted EPS attributable to IDEX was $1.61 versus $1.26. Adjusted diluted EPS, a non-GAAP measure reconciled in the filing, was $2.00 compared with $1.75. Gross margin declined to 44.9% from 45.3%, pressured by price/cost and unfavorable mix. Cash generation was steady: operating cash flow was $103.7 million and free cash flow was $86.0 million, compared with $91.4 million a year earlier. The company returned $76.3 million through share repurchases and $52.8 million in dividends. Borrowings rose to $1.88 billion, mainly from $100.0 million drawn under the $800.0 million Revolving Facility, which had $517.2 million of net availability at quarter-end. Cash and cash equivalents were $586.2 million, and the company remained in compliance with its debt covenants, with an interest coverage ratio of 13.85 to 1 and a leverage ratio of 1.93 to 1. The filing notes that tariffs enacted in 2025 and early 2026 had no material impact on results to date, and management expects to continue mitigating potential unfavorable effects. The quarter also included $7.4 million of restructuring expenses and asset impairments, including $4.8 million of impairments in the FMT segment, and a $3.7 million gain on a legal settlement. Remaining share repurchase authorization was $849.7 million at quarter-end.
Idex Annual Report, Year Ended Dec 31, 2025
IDEX Corporation reported record net sales of $3,457.5 million for 2025, up 6% from $3,268.8 million in 2024, with organic sales growth of 1%. Reported diluted EPS attributable to IDEX was $6.41, down from $6.64, while adjusted diluted EPS rose to $7.95 from $7.89. Management attributed the year's results to positive price across all segments and productivity gains from restructuring and cost containment, offset by lower volumes in the FMT and FSDP segments, higher interest expense, a higher effective tax rate of 23.7%, and higher acquisition-related amortization of $130.7 million. Cash generation remained strong, with operating cash flow of $680.4 million and free cash flow of $616.8 million. The company returned $248 million through share repurchases and $213 million in dividends. Cash and cash equivalents were $580.0 million, total borrowings were $1,829.8 million, and the Revolving Facility had $568.6 million of net availability at year-end. Covenant calculations showed an interest coverage ratio of 13.13 to 1 and a leverage ratio of 1.96 to 1, against required levels of 3.0 to 1 and 3.50 to 1, respectively. Looking ahead, management expects continued growth in HST, supported by data center, semiconductor, space and defense, and food and beverage and pharmaceutical demand. Industrial and automotive markets have not yet recovered, core industrial markets in FMT are tracking flat, and near-term headwinds are expected to persist in FSDP, particularly in Fire & Safety outside the United States and in Dispensing capital spending. The company also reported that Mr. Gillen joined as Senior Vice President and Chief Financial Officer in January 2026.
Idex 8-K Report, Executive Changes (Feb 9, 2026)
IDEX Corporation filed a Form 8-K under Item 5.02, which covers departures of directors or principal officers and compensatory arrangements for certain officers. The filing discloses a leadership change: on February 4, 2026, the company notified Roopa Unnikrishnan, Senior Vice President, Chief Strategy and Innovation Officer and a current named executive officer, that her position was being eliminated, effective February 28, 2026. The filing states that the company expects to enter into a separation agreement with Ms. Unnikrishnan under the terms of her letter agreement with the company for a termination without cause. The filing refers investors to the company's Proxy Statement filed with the SEC on March 26, 2025, for a description of that letter agreement. The 8-K does not disclose separation payment amounts or other financial terms. For investors, the key takeaway is a senior strategy executive's role being eliminated, with her departure effective at the end of February 2026. The filing does not state the reasons for the position's elimination or name a successor.
Idex 8-K Report, Financial Results (Feb 4, 2026)
IDEX Corporation (NYSE: IEX) furnished an 8-K on February 4, 2026, attaching a press release reporting fourth-quarter and full-year 2025 results. For the full year, net sales were $3,457.5 million, up 6% on a reported basis and 1% organically, with reported diluted EPS of $6.41 (down from $6.64) and adjusted diluted EPS of $7.95 (up from $7.89). Net income attributable to IDEX was $483.2 million versus $505.0 million in 2024, reflecting higher depreciation, amortization, restructuring costs, interest expense and taxes. The company cited a higher effective tax rate tied to 2025 legislation. Fourth-quarter net sales were $899.1 million, up 4% reported and 1% organic, and orders reached a record $979.2 million, up 20% reported and 16% organically, driven mostly by the HST segment. Management attributed HST order growth to AI-related projects, including data center power and semiconductor applications, while describing FMT and FSDP as operating in a challenging demand environment. Cash flow from operations for the year was $680.4 million and free cash flow was $616.8 million, with $247.8 million used for share repurchases. Free cash flow conversion was 103%. For 2026, IDEX projects full-year organic sales growth of 1% to 2% and adjusted diluted EPS of $8.15 to $8.35, and first-quarter organic sales growth of approximately 1% with adjusted diluted EPS of $1.73 to $1.78. The company does not reconcile these forward-looking non-GAAP measures to GAAP because the timing and magnitude of certain items cannot be reasonably estimated.
Idex 8-K Report, Executive Changes (Dec 4, 2025)
IDEX Corporation announced on December 4, 2025 that Sean M. Gillen, currently Chief Financial Officer of AAR CORP., will join as Senior Vice President and Chief Financial Officer effective January 5, 2026. Akhil Mahendra, who has served as Interim Chief Financial Officer, will return to his role as Vice President, Corporate Development on that date. The filing discloses Mr. Gillen's offer letter dated December 1, 2025, which provides an initial base salary of $625,000, a management incentive target of 85% of base salary beginning with the 2026 program, an annual equity grant with a targeted grant date fair value of $2,000,000, a new hire restricted stock award with a grant date fair value of $3,000,000 vesting in one-third installments on each anniversary of the grant date, and a cash sign-on bonus of $325,000 subject to repayment if he leaves or is terminated for cause before the 12-month anniversary of his start date. The filing also reports that Melissa S. Flores, Senior Vice President and Chief Human Resources Officer and a named executive officer, will resign effective December 19, 2025 to pursue another employment opportunity. According to the accompanying press release, the company intends to fill the role externally with a focus on talent strategy and culture, while leveraging existing leadership to oversee HR operations and administration in the interim. The press release (Exhibit 99.1) furnished under Item 7.01 quotes CEO Eric Ashleman describing the appointment as supporting the company's enterprise strategy, growth sectors, and 8020 approach. Mr. Gillen's stated priorities include improving margins and building on growth markets.
Idex 8-K Report, Financial Results (Oct 29, 2025)
IDEX Corporation reported third-quarter 2025 results for the period ended September 30, 2025, in a press release furnished as Exhibit 99.1 under Item 2.02. Record net sales were $878.7 million, up 10% on a reported basis and 5% organically, with the increase largely driven by the Mott Corporation acquisition completed in September 2024. Reported diluted EPS was $1.70 (up from $1.57), and adjusted diluted EPS was $2.03 (up from $1.90). Record orders were $880.3 million, up 13% reported and 7% organically. Gross margin was relatively flat at 44.5%, and operating cash flow of $203.5 million and free cash flow of $188.7 million were both roughly flat versus the prior year period. The company narrowed its full-year 2025 outlook, with GAAP diluted EPS now expected at $6.35 to $6.40 and adjusted diluted EPS at $7.86 to $7.91, both within prior guidance ranges. Full-year organic sales growth of approximately 1% was unchanged, and management expects at least 100% free cash flow conversion for the year and $60+ million in full-year savings from platform optimization and cost containment actions. Results were mixed by segment: Health & Science Technologies net sales rose 22% reported and 10% organically, Fluid & Metering Technologies rose 5% reported and 4% organically, and Fire & Safety/Diversified Products declined 3% reported and 5% organically. Capital deployment remained active. The company repurchased 461,500 shares for $75.0 million in the third quarter and $175 million year-to-date, increased its share repurchase authorization to $1 billion, and completed the Micro-LAM, Inc. acquisition for cash consideration of $80.7 million in July 2025. Interest expense rose to $16.5 million in the quarter from $10.3 million, reflecting debt raised for the Mott acquisition.
Idex Quarterly Report for Q3 Ended Sep 30, 2025
IDEX Corporation's third-quarter 2025 Form 10-Q reports record reported net sales of $878.7 million for the three months ended September 30, 2025, up from $798.2 million a year earlier, with net income attributable to IDEX of $127.8 million and diluted EPS of $1.70 versus $1.57. For the nine months, net sales were $2.56 billion and diluted EPS was $4.70 versus $5.02. Management attributes the growth largely to the Mott Corporation acquisition, with organic sales up 5% in the quarter and 1% year to date, and reports adjusted diluted EPS of $2.03 for the quarter. Restructuring charges of $18.3 million for the nine months relate to a 2025 initiative expected to cost about $20 million in total, primarily severance. Profitability was mixed. Gross margin was 44.5% for the quarter and 45.0% year to date, and Adjusted EBITDA reached $239.8 million in the quarter versus $214.3 million. Interest expense rose to $16.5 million in the quarter from $10.3 million, reflecting debt used to finance Mott, and the effective tax rate increased to 25.1% largely due to the enactment of the One, Big, Beautiful Bill Act. Management describes order trends as range-bound and notes customer hesitation around larger orders. The balance sheet remained solid, with cash of $593.8 million, total borrowings of $1.91 billion, and total equity of $4.01 billion. Operating cash flow for the nine months was $470.9 million and free cash flow was $427.0 million. The company repurchased $175.0 million of stock during the period and its board authorized an additional $635.0 million in repurchases in September 2025, leaving $999.7 million available. Credit ratings were reaffirmed at BBB (S&P), Baa2 (Moody's) and BBB+ (Fitch), and the company was in compliance with its financial covenants.
Idex 8-K Report, Regulation FD Disclosure (Sep 18, 2025)
On September 17, 2025, IDEX Corporation's Board of Directors authorized an additional $635 million share repurchase. Combined with the approximately $365 million that remained under previously approved authorizations, the company now has total repurchase availability of approximately $1 billion. The press release notes that this compares with approximately $440 million remaining as of June 30, 2025. The repurchases may be made in open market transactions, in privately negotiated transactions, or under 10b5-1 plans. Timing, volume and nature will be at management's discretion and depend on market conditions, other cash investment priorities, securities laws and other factors. The program does not obligate IDEX to buy any particular amount of stock and may be suspended or discontinued at any time. In the same release, IDEX's Board approved a regular quarterly cash dividend of $0.71 per common share, payable October 24, 2025 to shareholders of record as of October 10, 2025. This is the company's 124th consecutive regular quarterly cash dividend. CEO Eric D. Ashleman said IDEX expects to return at least 70% of free cash flow to shareholders in 2025 through dividends and repurchases, and that the company intends to deploy free cash flow toward bolt-on acquisitions and shareholder returns. He also noted that IDEX repurchased over $100 million of stock in the first half of 2025.
Idex Quarterly Report for Q2 Ended Jun 30, 2025
IDEX Corporation's second-quarter 2025 Form 10-Q reports net sales of $865.4 million for the three months ended June 30, 2025, up 7% from $807.2 million a year earlier, with the filing noting organic sales increased 1%, driven by the Mott Corporation acquisition. Reported diluted EPS attributable to IDEX was $1.74, down 6% from $1.86, reflecting higher amortization and interest expense tied to the Mott financing; the filing states adjusted diluted EPS of $2.07 was relatively flat. For the six months, net sales were $1,679.7 million (up 4%), and diluted EPS was $3.00 versus $3.46, with restructuring expenses rising to $18.2 million from $2.4 million due to organizational changes and severance. Gross margin was 45.3% for the quarter, essentially flat versus 45.4%, as price/cost and productivity gains offset volume deleverage and unfavorable mix. Segment Adjusted EBITDA was $260.1 million for the quarter, and consolidated Adjusted EBITDA was $237.2 million. Operating cash flow was $267.4 million for the six months, down from $290.2 million, and free cash flow was $238.3 million. Cash and equivalents stood at $568.2 million, total borrowings at $1,857.9 million, and the company repurchased $100.0 million of stock in the first half of 2025. Subsequent to the quarter, IDEX acquired Micro-LAM, Inc. on July 29, 2025 for $90.0 million in cash plus a potential earnout of up to $12.0 million, funded with revolver borrowings. The filing also states the company was in compliance with its financial covenants, with an interest coverage ratio of 12.94 to 1 against a 3.0 to 1 minimum and a leverage ratio of 2.08 to 1 against a 3.50 to 1 maximum.
Idex 8-K Report, Financial Results (Jul 30, 2025)
IDEX Corporation reported second-quarter 2025 results for the period ended June 30, 2025, with record net sales of $865.4 million, up 7% on a reported basis and 1% organically. Reported diluted EPS was $1.74, down from $1.86 a year earlier, while adjusted diluted EPS was $2.07, essentially flat versus $2.06. Orders were $829.8 million, up 7% reported and 2% organically, which management described as below the year-to-date average. Net sales growth was driven mainly by the Mott Corporation acquisition, while organic growth reflected positive price and targeted growth initiatives, partly offset by lower volumes in the Fluid & Metering Technologies segment. Management lowered its full-year 2025 outlook to GAAP diluted EPS of $6.30 to $6.44 and adjusted diluted EPS of $7.85 to $7.95, down from prior guidance of $6.56 to $6.95 and $8.10 to $8.45 respectively, based on expected full-year organic sales growth of approximately 1%. The CEO attributed the reset to a downshift in rapid-turn order trends exiting the quarter and customers taking a more cautious stance on larger orders, which delayed expected second-half acceleration in recently acquired businesses. For the third quarter, the company guided to GAAP diluted EPS of $1.54 to $1.61 and adjusted diluted EPS of $1.90 to $1.95, with organic sales growth of 2% to 3%. Cash generation improved, with operating cash flow of $161.7 million in the quarter, up from $133.6 million, and free cash flow of $146.9 million, up from $117.7 million. During the period the company repurchased 268,586 shares for $50.0 million in May 2025 and repaid $100.0 million of 3.37% Senior Notes in June 2025. In July 2025 it acquired Micro-LAM, Inc. for $90.0 million in cash plus a potential earnout of up to $12.0 million.
Idex 8-K Report, Executive Changes (May 21, 2025)
IDEX Corporation filed this Form 8-K under Item 5.02 to report a leadership change in its finance function. On May 19, 2025, Abhishek Khandelwal, Senior Vice President and Chief Financial Officer, notified the Company of his decision to resign, effective May 30, 2025, to pursue a new professional opportunity. The filing states that his departure is not the result of any disagreement with the Company's independent auditors or management on accounting principles, financial statement disclosure, or internal controls. The Company has retained an external search firm to identify candidates for the CFO role. On May 20, 2025, the Company appointed Akhil Mahendra as interim Chief Financial Officer, effective May 30, 2025, serving until a successor is appointed. Mahendra, 44, has been with the Company for approximately two years as Vice President, Corporate Development, and will continue in that role during the interim period. Previously he was Vice President, Corporate Development at Rivian Automotive, Inc. from 2020 to 2023, and before that worked in investment banking at Morgan Stanley. He holds a B.S. in Mechanical Engineering from Kettering University and an MBA from the University of Michigan. In connection with his interim appointment, the Compensation Committee approved a restricted stock award to Mahendra with a grant date fair value of $500,000. The award cliff vests three years after the grant date, subject to continued service, except as otherwise provided in the award agreement. The filing states there are no arrangements or understandings tied to his appointment, no family relationships with directors or executive officers, and no related-person transactions requiring disclosure under Item 404(a) of Regulation S-K.
Idex 8-K Report, Shareholder Vote Results (May 12, 2025)
IDEX Corporation's 8-K reports the results of its Annual Meeting of Stockholders, held May 8, 2025. Stockholders elected three Class III directors, Eric D. Ashleman, Stephanie J. Disher and Matthijs Glastra, to three-year terms expiring at the 2028 annual meeting. Each director received more votes for than against, but Disher drew the most opposition, with 3,347,060 votes against. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 59,216,982 votes in favor and 7,714,378 against. They ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2025, with 60,637,663 votes in favor and 8,839,575 against. A stockholder proposal calling for a report on hiring practices related to people with arrest or incarceration records did not pass, receiving 9,437,823 votes in favor and 55,577,864 against. The filing contains no financial results or operating disclosures. Its only listed exhibit is the Cover Page Interactive Data File (Exhibit 104).
Idex 8-K Report, Financial Results (May 1, 2025)
IDEX Corporation reported first-quarter 2025 results for the three months ended March 31, 2025, in a press release furnished as Exhibit 99.1 under Item 2.02. Orders were $871.9 million, up 6% from $820.3 million, with organic orders up 1%. Net sales were $814.3 million, up 2% from $800.5 million, but organic sales decreased 1%, driven by lower volumes in certain Fluid & Metering Technologies and Health & Science Technologies businesses. Reported diluted EPS was $1.26 versus $1.60 a year earlier, and adjusted diluted EPS was $1.75 versus $1.88. Net income attributable to IDEX was $95.5 million, down from $121.4 million, reflecting higher interest expense, depreciation, a higher effective tax rate, and higher restructuring and amortization costs. Management maintained its full-year 2025 organic sales growth guidance of 1% to 3% and GAAP diluted EPS guidance of $6.56 to $6.95 (adjusted diluted EPS of $8.10 to $8.45). For the second quarter, it guided to GAAP diluted EPS of $1.60 to $1.72 and adjusted diluted EPS of $1.95 to $2.05, based on organic sales growth of 0% to 2%. Management said it identified an additional $20 million of cost containment actions to offset potential tariff-related volume pressure and later-stage demand pressure, and that platform optimization efforts are on track for a total of $43 million impact in 2025. Cash flow weakened, with operating cash flow of $105.7 million (down from $156.6 million) and free cash flow of $91.4 million (down from $136.6 million), reflecting higher inventory build and interest payments on senior notes issued to fund the Mott acquisition. The company repurchased 256,159 shares for $50.0 million in February 2025 and had $249.0 million outstanding under its revolving credit facility at March 31, 2025, after repayments in January and April 2025.
Idex Quarterly Report for Q1 Ended Mar 31, 2025
IDEX Corporation's first quarter 2025 Form 10-Q reports net sales of $814.3 million, up 2% from $800.5 million a year earlier, while organic sales decreased 1%, reflecting lower volumes in parts of Fluid & Metering Technologies and Health & Science Technologies, partly offset by targeted growth initiatives and price capture. Diluted EPS attributable to IDEX was $1.26 versus $1.60, and the filing states adjusted diluted EPS was $1.75, down 7%. Operating income fell to $142.0 million from $161.2 million, driven by $17.5 million of restructuring expenses and asset impairments (versus $1.1 million) tied to 2025 severance actions, and by higher interest expense of $16.1 million from debt used to fund the Mott acquisition. Gross margin improved to 45.3% from 44.6%. Cash generation weakened in the quarter. Operating cash flow was $105.7 million compared with $156.6 million, and free cash flow was $91.4 million compared with $136.6 million, largely due to higher inventory investment and interest payments. The company repurchased $50.0 million of stock and repaid $30.2 million on its Revolving Facility, leaving $249.0 million drawn and about $548.0 million of net availability. Cash and cash equivalents were $594.1 million at March 31, 2025, and the company reported compliance with its financial covenants, with an interest coverage ratio of 14.08 to 1 and a leverage ratio of 2.22 to 1. Management states it expects the potential impact of tariffs and trade policy changes to be largely mitigated by price increases and cost reductions, and says short-cycle order patterns have not been discernibly disrupted to date. The filing also notes that the company expects an additional $3.5 million to $7.5 million of restructuring charges for the remainder of 2025.
Idex 8-K Report, Executive Changes (Feb 20, 2025)
IDEX Corporation (NYSE: IEX) filed a Form 8-K on February 20, 2025 reporting board changes under Item 5.02. On February 19, 2025, the Board appointed Stephanie Disher and Matthijs Glastra as directors, effective February 21, 2025. Ms. Disher will serve on the Nominating and Corporate Governance Committee and Mr. Glastra on the Audit Committee. Ms. Disher is Chief Executive Officer of Atmus Filtration Technologies Inc., and Mr. Glastra is Chair and Chief Executive Officer of Novanta Inc. In the same notice, directors David C. Parry and Livingston L. Satterthwaite informed the Company they will retire from the Board immediately following the 2025 Annual Meeting of Stockholders and will not stand for re-election. The Board size will increase from 10 to 12 directors and then fall to 10 after the annual meeting concludes. The filing states that neither new director has familial relationships or related-party transactions requiring disclosure, and both will receive the standard non-employee director compensation described in the March 26, 2024 proxy statement. The filing attaches a press release dated February 20, 2025 announcing the appointments and retirements. The release describes IDEX as a company with about 9,000 employees, manufacturing operations in more than 20 countries, and approximately $3.3 billion in annual sales. The changes are governance-related and do not include any financial results or guidance in this filing.
Idex Annual Report, Year Ended Dec 31, 2024
IDEX Corporation reported net sales of $3,268.8 million for 2024, essentially flat against $3,273.9 million in 2023, with organic net sales down 2% offset by a 2% contribution from acquisitions net of divestitures. Diluted EPS attributable to IDEX was $6.64, down 15% from $7.85, while adjusted diluted EPS was $7.89, down 4% from $8.22. Operating cash flow was $668.1 million, down 7%, and free cash flow was $603.0 million, down 4%. The Company's Health & Science Technologies segment saw the most pressure, with organic net sales down 10% amid cyclical softness in life sciences and semiconductor markets, while Fire & Safety/Diversified Products grew 4% in net sales. The defining event of 2024 was the acquisition of Mott Corporation on September 5, 2024, for cash consideration of $986.2 million, net of cash acquired. The Company funded it with $211.9 million of cash on hand, $279.3 million of Revolving Facility borrowings, and $495.0 million of net proceeds from a $500 million 4.950% Senior Notes offering due 2029. Mott is described as the Company's largest acquisition to date. Total borrowings rose to $1,971.3 million at December 31, 2024, from $1,333.3 million a year earlier, and the Company reported a 2.20 to 1 leverage ratio for covenant purposes against a 3.50 to 1 maximum. Looking ahead, management expects growth in HST from therapeutics, nutrition, satellite communications and datacenter-related energy demand, with semiconductor demand delayed until the second half of 2025. In early 2025 the Company began organizational changes and expects approximately $21 million to $25 million of severance-related restructuring charges. The Company also repurchased 256,159 shares for $50.0 million in February 2025, leaving $539.7 million of authorization remaining at year-end 2024.
Idex 8-K Report, Financial Results (Feb 4, 2025)
IDEX Corporation (NYSE: IEX) reported fourth quarter and full year 2024 results on February 4, 2025, furnished as Exhibit 99.1 to this Item 2.02 Form 8-K. For the quarter ended December 31, 2024, net sales rose to $862.9 million from $788.9 million, with orders of $816.8 million and organic sales up 3%. Reported diluted EPS was $1.62 versus $1.43, and adjusted diluted EPS was $2.04 versus $1.83. Operating cash flow fell to $172.6 million from $201.0 million, and free cash flow declined to $157.1 million from $179.4 million. Management attributed the sales increase largely to acquisitions, including Mott Corporation, and strong price capture. For full year 2024, net sales were $3,268.8 million, roughly flat with $3,273.9 million in 2023, and organic sales declined 2%. Net income attributable to IDEX fell to $505.0 million from $596.1 million, and reported diluted EPS was $6.64 versus $7.85. Adjusted diluted EPS was $7.89 versus $8.22. Operating cash flow was $668.1 million and free cash flow was $603.0 million, with free cash flow conversion of 101%. Health & Science Technologies saw softness in organic sales, while Fire & Safety/Diversified Products grew organically. For 2025, IDEX projected full-year organic sales growth of 1% to 3%, GAAP diluted EPS of $6.56 to $6.96, and adjusted diluted EPS of $8.10 to $8.45. First-quarter 2025 organic sales are projected to decline 3% to 4%, with GAAP diluted EPS of $1.18 to $1.24. Management cited geopolitical and economic uncertainty and reiterated a path toward double-digit earnings expansion.
Idex Quarterly Report for Q3 Ended Sep 30, 2024
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2024 shows third-quarter net sales of $798.2 million, up 1% from $793.4 million a year earlier, with organic net sales flat. Net income attributable to IDEX fell 43% to $119.1 million, and diluted EPS was $1.57 versus $2.75. The company attributes the softness largely to continued market headwinds in the Health & Science Technologies segment, which saw lower volumes, partly offset by price capture and productivity across segments. Adjusted EBITDA was $214.3 million versus $225.5 million, and adjusted diluted EPS was $1.90 versus $2.12. The prior-year quarter included a $93.8 million pre-tax gain on the sale of Micropump, which explains much of the decline in reported earnings. For the nine months, net sales were $2,405.9 million, down 3% from $2,485.0 million, and organic net sales decreased 3%. Diluted EPS was $5.02 versus $6.42. Operating cash flow was $495.5 million and free cash flow was $445.9 million, roughly flat with the prior year. The most significant event of the period was the September 5, 2024 acquisition of Mott Corporation for cash consideration of $986.2 million, funded with cash on hand, $279.3 million of Revolving Facility borrowings, and $495.0 million of net proceeds from new 4.950% Senior Notes due 2029. Total borrowings rose to $2,087.4 million from $1,333.3 million at year-end 2023. Liquidity remains solid, with $633.2 million of cash and cash equivalents, $436.7 million of available Revolving Facility capacity, and compliance with financial covenants (interest coverage of 18.19 to 1 versus a 3.0 to 1 minimum, and leverage of 2.39 to 1 versus a 3.50 to 1 maximum). Subsequent to quarter end, the company repaid $69.1 million under the Revolving Facility and the remaining $25.0 million under the Term Facility. Credit ratings were reaffirmed by S&P (BBB, stable), Moody's (Baa2, stable) and Fitch (BBB+, stable).
Idex 8-K Report, Financial Results (Oct 30, 2024)
IDEX Corporation (NYSE: IEX) reported third-quarter 2024 results in a press release dated October 29, 2024, furnished with this Form 8-K. Net sales were $798.2 million, up 1% overall and flat on an organic basis, with lower volumes in the Health & Science Technologies segment offset by price capture. Orders rose to $780.5 million from $712.3 million, and organic orders increased 8%. Reported diluted EPS fell to $1.57 from $2.75, down 43%, mainly because the prior-year period included the gain on the sale of the Micropump business. Adjusted diluted EPS was $1.90, down 10%, and adjusted EBITDA margin was 26.9%, down 150 bps, as higher employee-related costs and lower volume outweighed price/cost gains. Operating cash flow was $205.3 million, down 9%, and free cash flow was $191.6 million, down 7%. The company completed its acquisition of Mott Corporation on September 5, 2024, for cash consideration of $986.2 million, net of $3.1 million of cash acquired. IDEX states that the net transaction value, after the present value of expected tax benefits of approximately $100 million, is about $900 million, or roughly 19x Mott's forecasted full-year 2024 EBITDA. The company expects the acquisition to be accretive to adjusted earnings per share in fiscal 2026. During the quarter, IDEX also completed a public offering of $500 million principal amount of 4.950% Senior Notes due September 2029. For full-year 2024, IDEX projects organic sales to decline 1% to 2%. It raised the low end of its adjusted diluted EPS guidance to $7.85 to $7.90 from $7.80 to $7.90, and lowered its GAAP diluted EPS guidance to $6.65 to $6.70 from $6.85 to $6.95. The company attributes the GAAP change to purchase accounting impacts, including acquisition-related amortization from Mott. Management stated that segment-level orders and backlog trends, particularly in Health & Science Technologies, will be key indicators to watch as the company looks for signs of recovery in life science and semiconductor markets.
Idex 8-K Report, Regulation FD Disclosure (Sep 5, 2024)
IDEX Corporation, a Delaware corporation headquartered in Northbrook, Illinois, reported in this Form 8-K dated September 5, 2024 that it completed its previously announced acquisition of Mott Corporation, a Connecticut corporation, and its subsidiaries. The filing furnishes a press release (Exhibit 99.1) under Item 7.01 and reports the closing under Item 8.01 (Other Events). The filing does not state the purchase price or other deal financial terms. According to the press release, Mott is a leader in the design and manufacturing of sintered porous material structures and flow control solutions, with more than 60 years of history serving global OEMs and technology brands. IDEX expects Mott to join its Health & Science Technologies segment, expanding its applied material science capabilities and increasing opportunities in semiconductor wafer fabrication equipment, energy transition, medical technologies, space & defense, and water purification. Management also expects the acquisition to complement recent integrations of Muon Group, Iridian Spectral Technologies, and STC Material Solutions, and to create value through implementation of 8020 and the IDEX Operating Model. CEO Eric D. Ashleman described the deal as an important step in IDEX's strategy to deliver long-term, compounding value to customers, employees, and shareholders. The press release notes that IDEX has approximately $3.3 billion in annual sales and about 8,800 employees across more than 50 businesses. The filing does not disclose Mott's revenue, earnings, or the financial effect of the transaction on IDEX's results.
Idex 8-K Report, Material Agreement (Aug 21, 2024)
IDEX Corporation completed an underwritten public offering on August 21, 2024 of $500.0 million aggregate principal amount of 4.950% Senior Notes due 2029, issued under a shelf registration statement on Form S-3ASR. Net proceeds were approximately $495.0 million after the underwriting discount and estimated offering expenses of approximately $1.7 million. The company intends to use the proceeds, together with revolving credit facility borrowings and cash on hand, to fund the cash consideration for its previously announced acquisition of Mott Corporation and its subsidiaries (the "Mott Acquisition") and to pay related fees and expenses. The Notes are senior, unsecured obligations, equal in right of payment with the company's existing and future senior unsecured debt and senior to subordinated debt. They are effectively subordinated to future secured debt and structurally subordinated to all liabilities of subsidiaries, since the Notes are not guaranteed by any subsidiary. Interest is payable semi-annually on March 1 and September 1, beginning March 1, 2025, with maturity on September 1, 2029. The company may redeem the Notes before the August 1, 2029 par call date at a make-whole price based on the Treasury Rate plus 20 basis points, and at 100% of principal thereafter. The Indenture includes covenants limiting liens, certain sale-leaseback transactions, and certain consolidations, mergers, or asset sales. A special mandatory redemption provision requires the company to redeem all Notes at 101% of principal plus accrued interest if the Mott Acquisition is not consummated by the Special Mandatory Redemption End Date (the later of November 20, 2024, or any extended outside date under the Mott Acquisition Agreement), if that agreement is terminated without closing, or if the company notifies the trustee it will not pursue the acquisition. A change of control triggering event requires an offer to repurchase at 101% of principal plus accrued interest.
Idex 8-K Report, Material Agreement (Aug 8, 2024)
IDEX Corporation entered into an Underwriting Agreement dated August 7, 2024 with Wells Fargo Securities, LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the several underwriters, under which the company agreed to issue and sell $500.0 million in aggregate principal amount of its 4.950% Senior Notes due 2029. The underwriters agreed to purchase the notes for resale to the public. The offering is expected to close on August 21, 2024, subject to customary closing conditions. The notes are being offered under the company's effective shelf registration statement on Form S-3ASR (File No. 333-277309), filed February 23, 2024, and a related prospectus supplement filed August 7, 2024. They will be issued under a 2010 indenture with Computershare Trust Company, N.A., as successor trustee, as supplemented by a Fifth Supplemental Indenture to be dated the closing date. IDEX intends to use the net proceeds, together with available revolving credit facility borrowings and cash on hand, to fund the cash consideration for its previously announced acquisition of Mott Corporation and its subsidiaries, and to pay related fees and expenses. The underwriting agreement contains customary representations, warranties, covenants, and indemnification provisions. Certain underwriters and their affiliates have provided, and may in the future provide, commercial banking, derivatives, advisory, and other services to the company for customary fees.
Idex Quarterly Report for Q2 Ended Jun 30, 2024
IDEX Corporation reported second-quarter 2024 net sales of $807.2 million, down 5% from $846.2 million a year earlier, with organic net sales down 4%. The decline reflected lower volumes, largely in the Health & Science Technologies segment, partly offset by price capture and strong price/cost and productivity across segments. Net income attributable to IDEX rose 2% to $141.3 million, and diluted EPS increased to $1.86 from $1.82. Adjusted net income attributable to IDEX fell 6% to $156.1 million, and Adjusted EBITDA declined 7% to $224.2 million, with the Adjusted EBITDA margin at 27.8% versus 28.4%. Gross margin improved to 45.4% from 44.7%, and operating income fell 9% to $182.7 million. For the first half of 2024, net sales were $1,607.7 million, down 5%, and net income attributable to IDEX was $262.7 million. Cash flow from operations was $290.2 million, and free cash flow was $254.3 million. Cash and cash equivalents totaled $700.7 million at June 30, 2024, and the Revolving Facility had $719.2 million of net availability. The company paid $100.7 million in dividends during the six months and made no share repurchases, leaving $539.7 million of authorization remaining. The company was in compliance with its financial covenants at June 30, 2024. Looking ahead, IDEX entered into a definitive agreement on July 23, 2024 to acquire Mott Corporation for $1.0 billion in cash, expected to close by the end of the third quarter of 2024 subject to regulatory approvals. The acquisition is expected to be funded with cash on hand, borrowings under the Revolving Credit Facility and potential debt issuance. The company also acquired Subterra AI, Inc. for $7.5 million on July 25, 2024.
Idex 8-K Report, Financial Results (Aug 1, 2024)
IDEX Corporation reported second-quarter 2024 net sales of $807 million, down 5% overall and down 4% organically, against $846 million a year earlier. Reported diluted EPS rose to $1.86 from $1.82, while adjusted diluted EPS fell 6% to $2.06. Gross margin increased 70 bps to 45.4%, driven mainly by price/cost and operational productivity, while adjusted EBITDA margin declined 60 bps to 27.8%, reflecting lower volume leverage and unfavorable mix. Operating cash flow was $134 million, down 5%, and free cash flow was $118 million, down 2%. The Health & Science Technologies segment, with organic net sales down 11%, was the main source of weakness, while Fluid & Metering Technologies was flat organically and Fire & Safety/Diversified Products rose 1%. The company lowered its full-year 2024 outlook. Organic sales are now projected to decline 1% to 2%, versus prior guidance of an increase of 0% to 2%. GAAP diluted EPS guidance is $6.85 to $6.95 (adjusted $7.80 to $7.90), down from $7.13 to $7.43 (adjusted $8.15 to $8.45). For the third quarter, organic sales are projected to be 0% to 1% higher year over year, with GAAP diluted EPS of $1.61 to $1.66 and adjusted diluted EPS of $1.85 to $1.90. Management cited uncertainty-fueled macro headwinds and project delays in industrial markets, and noted that the Semiconductor and Life Sciences & Analytical Instrumentation markets have not yet launched a recovery. On capital deployment, IDEX entered into a definitive agreement on July 23, 2024 to acquire Mott Corporation and its subsidiaries for $1.0 billion in cash, subject to customary adjustments, with closing expected by the end of the third quarter of 2024. The company also divested Alfa Valvole Srl for $45.5 million in cash, recognizing a gain of $4.6 million, and repaid $25.0 million of the $50.0 million outstanding under its term facility. Cash and cash equivalents were $700.7 million at June 30, 2024, compared with $534.3 million at December 31, 2023.
Idex 8-K Report, Regulation FD Disclosure (Jul 23, 2024)
IDEX Corporation (NYSE: IEX) has entered into a definitive agreement to acquire Mott Corporation and its subsidiaries from the Mott Corporation Employee Stock Ownership Trust, for cash consideration of $1 billion, subject to customary adjustments. Mott is described as a leading microfiltration business specializing in the design, customization, and manufacturing of sintered porous metal components and engineered solutions used in fluidic applications. Adjusted for the present value of expected tax benefits of approximately $100 million, the net transaction value is approximately $900 million, which the company says represents approximately 19x Mott's forecasted full year 2024 EBITDA and a mid-teens multiple based on forecasted 2025 EBITDA. IDEX expects Mott to generate approximately $200 million of revenue in 2024 with an EBITDA margin in the low 20s, and will fold it into its Health & Science Technologies segment. The transaction is expected to be accretive to adjusted earnings per share in fiscal 2026 and to deliver a double-digit return on invested capital in year five after closing. Management frames the deal as an extension of its applied materials science portfolio, alongside the recently acquired Muon Group, Iridian Spectral Technologies, and STC Material Solutions, with target markets including semiconductor wafer fab equipment, energy transition, medical technologies, space and defense, and water purification. The transaction will be funded through cash on hand, borrowings under IDEX's current credit facility, and potential debt issuance, and is not subject to any financing conditions. The company expects net leverage of approximately 1.8x at closing. Closing is expected by the end of the third quarter of 2024, subject to regulatory approvals and customary closing conditions.
Idex 8-K Report, Shareholder Vote Results (May 8, 2024)
IDEX Corporation reported the results of its Annual Meeting of Stockholders, held May 7, 2024, in an Item 5.07 disclosure. Stockholders elected three Class II directors, Mark A. Buthman, Lakecia N. Gunter and L. Paris Watts-Stanfield, to three-year terms expiring at the 2027 annual meeting. Each received more votes for than against, with Watts-Stanfield receiving the widest margin, at 68,179,259 for and 403,994 against. Stockholders also voted on three company proposals. They approved, on an advisory basis, the compensation of the named executive officers (61,787,864 affirmative votes versus 5,922,861 negative), approved the IDEX Corporation 2024 Incentive Award Plan (62,284,526 affirmative versus 5,427,757 negative), and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2024 (63,061,818 affirmative versus 7,014,160 negative). A stockholder proposal calling for a report on hiring practices related to people with arrest or incarceration records did not pass. It received 11,130,090 affirmative votes against 54,948,151 negative votes, with 2,514,544 abstentions and 1,531,949 broker non-votes. The filing also lists a Cover Page Interactive Data File (Exhibit 104) as its only exhibit.
Idex Quarterly Report for Q1 Ended Mar 31, 2024
IDEX Corporation reported first-quarter 2024 net sales of $800.5 million, down from $845.4 million in the prior-year quarter, with organic net sales declining 6% as lower volumes in the Health & Science Technologies segment offset price capture across all segments. Net income attributable to IDEX was $121.4 million, or $1.60 diluted EPS, compared with $139.8 million and $1.84 a year earlier. Gross margin fell to 44.6% from 45.2%, and operating income declined to $161.2 million from $192.3 million, with the filing citing lower volume leverage and higher employee-related costs. Adjusted diluted EPS was $1.88 versus $2.09, per the company's non-GAAP reconciliation. Cash generation remained solid. Cash flows from operating activities rose to $156.6 million from $147.9 million, driven mainly by lower cash payments for variable compensation, and free cash flow was $136.6 million versus $121.3 million. Cash and cash equivalents increased to $616.3 million at March 31, 2024, while total borrowings were $1,330.9 million and the Revolving Facility had $717.8 million of net availability. The company made no share repurchases during the quarter, leaving $539.7 million of authorization remaining, and paid $48.5 million in dividends. The Health & Science Technologies segment was the main source of weakness, with net sales down 12% and Adjusted EBITDA down 19%, attributed to inventory recalibration and market slowness in analytical instrumentation, life sciences and semiconductor markets. Fluid & Metering Technologies sales declined 3%, while Fire & Safety/Diversified Products grew 2%. The company stated it expects no material impact from the OECD Pillar Two global minimum tax rules.
Idex 8-K Report, Financial Results (Apr 24, 2024)
IDEX Corporation reported first-quarter 2024 results for the period ended March 31, 2024, with net sales of $800.5 million, down 5% overall and down 6% on an organic basis, which the filing describes as in line with expectations. Reported diluted EPS was $1.60 versus $1.84 a year earlier, and adjusted diluted EPS was $1.88 versus $2.09, which the company says exceeded first-quarter expectations. Operating cash flow was $156.6 million and free cash flow was $136.6 million, up 15.3 million from the prior-year period, and the company reduced its net debt position through strong cash generation, with cash and cash equivalents rising to $616.3 million at quarter-end. By segment, Fluid & Metering Technologies (FMT) sales were $313.7 million and adjusted EBITDA margin improved to 33.6%, Fire & Safety/Diversified Products (FSDP) sales rose 2% organically to $178.0 million with margin expanding to 28.9%, and Health & Science Technologies (HST) sales fell 13% organically to $310.1 million with adjusted EBITDA margin declining 250 bps to 26.2%. Management cited an encouraging sequential lift in orders from core industrial and municipal markets, while noting uneven recovery across HST's targeted end markets. IDEX confirmed its full-year 2024 guidance, projecting organic sales growth of 0% to 2%, GAAP diluted EPS of $7.13 to $7.43, and adjusted diluted EPS of $8.15 to $8.45. For the second quarter, it projects organic sales declines of 2% to 3% and adjusted diluted EPS of $2.00 to $2.05.
Idex Annual Report, Year Ended Dec 31, 2023
IDEX Corporation (IEX) reported 2023 net sales of $3,273.9 million, up 3% from $3,181.9 million in 2022, with organic net sales declining 1%. Net income attributable to IDEX was $596.1 million, up 2%, and diluted EPS was $7.85 versus $7.71. Adjusted EBITDA rose 2% to $899.6 million, and the company generated record free cash flow of $626.8 million on operating cash flow of $716.7 million. Growth was driven by a 5% contribution from acquisitions net of divestitures and price capture, partially offset by lower volumes, particularly in the Health & Science Technologies segment, as customers destocked inventory. The company operates three reportable segments: Fluid & Metering Technologies (42% of segment Adjusted EBITDA), Health & Science Technologies (37%), and Fire & Safety/Diversified Products (21%). During 2023 IDEX acquired Iridian Spectral Technologies for $109.8 million and STC Material Solutions for $202.0 million, and sold Micropump for $110.3 million, recording a pre-tax gain of $93.8 million. Total borrowings were $1,333.3 million at year-end, with cash and cash equivalents of $534.3 million, and the company was in compliance with its financial covenants, with an interest coverage ratio of 18.43 to 1 and a leverage ratio of 1.45 to 1. Management stated that the majority of its businesses were seeing stable demand and early signs of improvement, particularly in Fluid & Metering Technologies, while life sciences and analytical instrument markets were not yet showing near-term recovery. The Dispensing reporting unit is expected to contract in 2024 following completion of a North American fleet refreshment cycle in 2023.
Idex 8-K Report, Financial Results (Feb 7, 2024)
IDEX Corporation (NYSE: IEX) reported fourth quarter and full year 2023 results in a press release dated February 6, 2024 (Exhibit 99.1), with slides for its February 7, 2024 earnings call furnished as Exhibit 99.2. For Q4 2023, sales were $788.9 million, down 3% overall and down 6% organically, while reported diluted EPS was $1.43 (down 16%) and adjusted diluted EPS was $1.83 (down 9%). Operating cash flow of $201.0 million and free cash flow of $179.4 million were both up year over year. For full year 2023, the company reported record net sales of $3,273.9 million (up 3%, but down 1% organically), record reported diluted EPS of $7.85, record adjusted diluted EPS of $8.22 (up 1%), and record free cash flow of $626.8 million (up 28%). management said most end markets are stable and that the company is in the early stages of focused organic growth. However, the timing of recovery in its Life Sciences and Analytical Instrumentation businesses remains uncertain, which moderates the full-year growth outlook. Orders fell 6% in Q4 and 7% for the full year, with organic orders down 10% and 11% respectively. During the quarter the company completed the $202.0 million cash acquisition of STC Material Solutions and the sale of Novotema for $8.3 million, which produced a $9.1 million loss. For 2024, IDEX guided to full-year organic sales growth of 0% to 2%, reported diluted EPS of $7.15 to $7.45, and adjusted diluted EPS of $8.15 to $8.45. First-quarter 2024 organic sales are projected to decline 6% to 7%, with adjusted diluted EPS of $1.70 to $1.75. Guidance excludes future acquisitions and restructuring expenses.
Idex 8-K Report, Financial Results (Oct 26, 2023)
IDEX Corporation (NYSE: IEX) reported third-quarter 2023 net sales of $793.4 million, down 4% overall and down 6% organically, compared with the third quarter of 2022. Reported diluted EPS was $2.75, up 17%, but adjusted diluted EPS was $2.12, down 1%, which management attributed in part to a lower effective tax rate. Operating cash flow was $227 million, up 14%, and free cash flow was a record $207 million, up 14%. Gross margin was 44.1%, down 220 basis points, driven mainly by the 2022 acceleration of deferred revenue tied to a COVID-19 testing application that did not recur in 2023, along with lower volume leverage and unfavorable mix. The company completed the sale of Micropump, Inc. for $110 million in cash, which produced a pre-tax gain of $93.8 million. During the quarter IDEX also repaid $150.0 million of the $200.0 million outstanding under its term facility. Management said the divergent destocking rates in its end markets have largely run their course, and it expects order rate stability for the balance of 2023. The company welcomed Abhi Khandelwal as SVP and Chief Financial Officer. IDEX raised its full-year 2023 guidance. Reported GAAP diluted EPS is now projected at $7.91 to $7.96, up from $6.80 to $6.90, and adjusted diluted EPS at $8.13 to $8.18, up from $7.90 to $8.00. Full-year organic sales are projected to decline 1% to 2%, while fourth-quarter organic sales are projected to decline 8% to 9%, with fourth-quarter adjusted EPS of $1.74 to $1.79.
Idex Quarterly Report for Q3 Ended Sep 30, 2023
IDEX Corporation's Form 10-Q for the quarter ended September 30, 2023 shows third-quarter net sales of $793.4 million, down from $824.0 million a year earlier, while net income attributable to IDEX rose to $209.1 million from $178.7 million. The filing attributes the net sales decline to lower volumes in the Health & Science Technologies segment, where customer inventory recalibration reduced demand, partially offset by price capture across all segments. Net income was boosted by a pre-tax gain of $93.8 million on the sale of the Micropump business, which the filing says contributed a $71.1 million gain, net of tax. Diluted EPS was $2.75 versus $2.36, while adjusted diluted EPS was $2.12 versus $2.14 as reported in the filing's non-GAAP reconciliation. For the nine months, net sales rose to $2,485.0 million from $2,371.2 million and net income attributable to IDEX reached $487.5 million versus $456.9 million. Cash flow from operating activities was $515.7 million for the nine months, compared with $390.1 million a year earlier, and free cash flow was $447.4 million versus $342.1 million. The company reported cash and cash equivalents of $562.7 million, total borrowings of $1,329.4 million, and repaid $150.0 million of its Term Facility during the quarter. Management said it believes customer destocking efforts are largely complete and expects orders to stabilize and lead times to normalize during the fourth quarter of 2023. The filing notes an interim gross margin of 44.1% for the quarter versus 46.3% a year earlier, and an adjusted EBITDA of $225.5 million versus $231.4 million. Covenant compliance was reported, with an interest coverage ratio of 18.62 to 1 and a leverage ratio of 1.42 to 1 against required levels of 3.0 to 1 and 3.50 to 1, respectively.
Idex 8-K Report, Executive Changes (Oct 25, 2023)
IDEX Corporation (NYSE: IEX) announced on October 25, 2023 that Abhishek Khandelwal (also referred to in the press release as Abhi Khandelwal) will join as Senior Vice President and Chief Financial Officer, effective November 20, 2023. Mr. Khandelwal previously served at IDEX from 2010 until March 2020, most recently as Vice President of Finance Operations, Treasury and Financial Planning & Analysis. He most recently served as Chief Financial Officer of Multi-Color Corporation since January 2022, and before that as Senior Vice President and Chief Financial Officer of CIRCOR International, Inc. from April 2020 until December 2021. Upon his start date, Allison S. Lausas will cease serving as Interim Chief Financial Officer, a role she has held since September 2023, and will continue as Vice President and Chief Accounting Officer. CEO and President Eric Ashleman praised Ms. Lausas's leadership during the interim period. The filing sets out Mr. Khandelwal's compensation under an offer letter dated October 20, 2023: an initial base salary of $575,000, a 2024 incentive target of 75% of base salary, annual equity grants with a grant date fair value of $1,300,000, a new hire equity award with a grant date fair value of $2,000,000, and a $300,000 sign-on bonus subject to repayment if he leaves or is terminated for cause before the 12-month anniversary of his start date. Severance equals 12 months of base salary and target annual incentive upon termination without cause, rising to two times that amount if terminated within 24 months after a change in control.
Idex 8-K Report, Executive Changes (Aug 30, 2023)
IDEX Corporation (IEX), listed on the New York Stock Exchange, filed this Current Report on Form 8-K, dated August 24, 2023 and signed August 30, 2023, to disclose a leadership change. The filing reports that, as part of an internal reorganization of certain leadership positions, the company notified Marc Uleman, Senior Vice President, Group Executive, Health & Science Technologies, on August 24, 2023 that his position was being eliminated. The elimination takes effect September 11, 2023, and Mr. Uleman will no longer serve in an executive role after that date. The filing does not report any financial results, guidance, or other operating information, and it discloses no financial impact from the change. For investors, this is a limited, executive-level organizational update within the Health & Science Technologies group. The filing is signed by William K. Grogan, Senior Vice President and Chief Financial Officer.
Idex 8-K Report, Executive Changes (Aug 30, 2023)
IDEX Corporation announced on August 30, 2023 that Senior Vice President and Chief Financial Officer William K. Grogan is resigning to pursue a new professional opportunity, and that Allison S. Lausas will serve as interim Chief Financial Officer. Both changes are effective September 15, 2023. The filing states that Grogan's departure is not the result of any disagreement with the company's independent auditors or management on accounting principles, financial statement disclosure, or internal controls. Lausas, 43, has been with IDEX for two years as Vice President and Chief Accounting Officer and will keep that role during the interim period. She previously held roles of increasing responsibility at SunCoke Energy, Inc. from 2011 to 2021, most recently as interim Senior Vice President, Chief Financial Officer and Controller, and spent nine years at KPMG. In connection with her interim appointment, the Compensation Committee approved an award of 2,200 shares of restricted stock that cliff vests three years after the grant date, subject to continued service. IDEX has begun a search for a permanent CFO, considering both internal and external candidates. The filing describes IDEX as a company with more than 8,500 employees, manufacturing operations in more than 20 countries, and over $3.1 billion in annual sales.
Idex 8-K Report, Financial Results (Jul 27, 2023)
IDEX Corporation reported record second-quarter 2023 net sales of $846.2 million, up 6% overall and 3% organically, with reported diluted EPS of $1.82 (up 1%) and record adjusted diluted EPS of $2.18 (up 8%). Operating cash flow was $141.2 million and free cash flow was $119.6 million, up 24% from the prior year period. The company also lowered its full-year 2023 outlook: organic sales are now projected to decline 1 to 2 percent, with GAAP EPS of $6.80 to $6.90 and adjusted EPS of $7.90 to $8.00. Third-quarter organic sales are projected to decline 7 to 8 percent, with adjusted EPS of $1.84 to $1.89. management attributed the weaker outlook to its Health & Science Technologies segment, where customers' sharp inventory recalibration and demand softness followed two years of double-digit growth. Management said it no longer expects a market recovery in the second half of the year and is pursuing targeted cost reductions. Fluid & Metering Technologies and Fire & Safety / Diversified Products delivered strong organic growth and margin expansion. HST net sales were $339.5 million, with adjusted EBITDA margin down 420 basis points to 27.6%. Other developments in the filing include the completion of the Iridian Spectral Technologies acquisition on May 19, 2023 for $110.3 million in cash, and a $100.0 million private placement of 5.13% Senior Notes due 2028 used to repay 3.20% Senior Notes due June 13, 2023. Second-quarter net income margin fell 90 basis points to 16.4%, reflecting a reserve on an investment with a collaborative partner, higher amortization and higher interest expense.
Idex Quarterly Report for Q2 Ended Jun 30, 2023
IDEX Corporation reported record second-quarter 2023 net sales of $846.2 million, up 6% from $796.1 million a year earlier, with organic net sales growth of 3%. Net income attributable to IDEX was $138.6 million, compared with $138.2 million, and diluted EPS was $1.82, up 1%. Adjusted diluted EPS rose 8% to $2.18, and Adjusted EBITDA increased 10% to $240.7 million, a 28.4% margin. For the six months, net sales were $1,691.6 million, up 9%, and operating cash flow was $289.1 million, compared with $192.0 million a year earlier. Free cash flow was $240.9 million, which the filing attributes mainly to lower investments in working capital. Segment performance was mixed. Fluid & Metering Technologies and Fire & Safety/Diversified Products grew, while Health & Science Technologies was challenged by customer inventory recalibration in the Analytical Instrumentation, Life Science and Biopharma markets, and its second-quarter Adjusted EBITDA fell 10% to $93.7 million. Management expects revenues and earnings in the second half of 2023 to be lower than in the first half, driven by market-based declines in both the FMT and HST segments. During the period, IDEX acquired Iridian for $110.3 million in cash and recorded a $7.7 million credit loss on a note receivable from a collaborative partner. It also issued $100 million of 5.13% Senior Notes due 2028 and used the proceeds to repay the 3.20% Senior Notes due June 2023. At June 30, 2023, cash and cash equivalents were $457.0 million and total borrowings were $1,480.5 million. The company stated it was in compliance with its financial covenants, with a leverage ratio of 1.52 to 1 and an interest coverage ratio of 21.03 to 1.
Idex 8-K Report, Material Agreement (Jun 14, 2023)
IDEX Corporation completed a private placement on June 13, 2023 of $100 million aggregate principal amount of 5.13% Series C Senior Notes due June 13, 2028 (the "2028 Notes") under a Note Purchase and Master Note Agreement with NYL Investors LLC and certain affiliates of New York Life. The company used the proceeds to repay its 3.20% Series A Senior Notes due June 13, 2023, which were issued under a 2016 Note Purchase Agreement. The 2028 Notes are unsecured and rank pari passu with the company's other unsecured, unsubordinated debt, and they have not been registered under the Securities Act of 1933. The Purchase Agreement also establishes a shelf facility allowing IDEX to issue additional unsecured senior notes ("Shelf Notes") to New York Life affiliates and managed accounts, up to $300 million less the amount of outstanding 2028 Notes and senior notes under the 2016 agreement (currently $100 million of Series B Senior Notes due June 13, 2025). Shelf Notes may be issued through June 12, 2026, with maturities of no more than 15 years and rates to be mutually agreed after IDEX requests a purchase. The agreement contains restrictive covenants limiting asset transfers and sales, liens, indebtedness, affiliate transactions, and certain mergers or consolidations, and requires compliance with a leverage ratio, interest coverage ratio, and priority debt ratio. IDEX may prepay notes at par plus accrued interest plus a make-whole amount, in minimum increments of 5% of the outstanding series, and customary events of default apply.
Idex 8-K Report, Shareholder Vote Results (May 31, 2023)
IDEX Corporation filed this Form 8-K to report the results of its Annual Meeting of Stockholders, held on May 25, 2023. Stockholders elected four Class I directors, Katrina L. Helmkamp, Mark A. Beck, Carl R. Christenson and Alejandro Quiroz Centeno, to three-year terms expiring at the 2026 annual meeting. Votes for each nominee were 61,440,895, 54,152,966, 63,068,104 and 68,741,243, respectively, and each nominee received more votes for than against. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 65,328,418 affirmative votes against 3,605,508 negative votes. On the frequency of future advisory say-on-pay votes, a majority favored one year (68,633,788 votes), compared with 31,065 for two years and 549,410 for three years. Based on this result, the Board determined that the company will hold the advisory compensation vote every year. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2023, with 67,107,495 votes for and 3,369,771 against. A stockholder proposal calling for a report on hiring practices related to people with arrest or incarceration records did not pass, receiving 12,634,525 affirmative votes against 55,573,427 negative votes and 1,065,885 abstentions. Broker non-votes totaled 1,250,659 on the director, say-on-pay, frequency and stockholder proposal items, and the filing lists the Inline XBRL cover page as its only exhibit.
Idex Quarterly Report for Q1 Ended Mar 31, 2023
IDEX Corporation's Form 10-Q for the quarter ended March 31, 2023 reports net sales of $845.4 million, up 13% from $751.1 million a year earlier, with organic sales up 6%. Net income attributable to IDEX was $139.8 million, essentially flat versus $140.0 million, and diluted EPS rose to $1.84 from $1.83. The filing states adjusted diluted EPS of $2.09, up $0.13 or 7%, and Adjusted EBITDA of $229.8 million, up 7%, with the Adjusted EBITDA margin of 27.2% down 140 basis points. Net sales growth was driven by acquisitions (Muon Group, KZValve, Nexsight), partly offset by a 2% unfavorable foreign currency impact. Operating income rose to $192.3 million from $187.6 million, while interest expense increased to $13.1 million from $9.5 million, reflecting borrowings used for the Muon Group acquisition. Cash flow strengthened considerably. Operating cash flow was $147.9 million, up from $79.7 million, mainly due to lower working capital investment. Free cash flow was $121.3 million, compared with $63.6 million in the prior year. Cash and cash equivalents rose to $510.7 million at March 31, 2023. Total borrowings were $1,479.5 million, and the company stated it was in compliance with its financial covenants. No share repurchases occurred in the quarter, and $563.8 million remained under the authorization. Subsequent to quarter end, on April 25, 2023, IDEX agreed to acquire Iridian Spectral Technologies for cash consideration of 150.0 million Canadian dollars, with closing expected by the end of the second quarter of 2023. The filing also notes that the 3.20% Senior Notes due June 2023 ($100.0 million) are expected to be refinanced or repaid using the Revolving Credit Facility.
Idex 8-K Report, Financial Results (Apr 27, 2023)
IDEX Corporation (NYSE: IEX) reported first-quarter 2023 results on April 26, 2023, with record net sales of $845.4 million, up 13% overall and 6% organically compared with $751.1 million in the first quarter of 2022. Reported diluted EPS was $1.84 (up 1%), and adjusted diluted EPS was $2.09 (up 7%). Net income attributable to IDEX was flat at $139.8 million. Operating cash flow rose to $147.9 million and free cash flow to $121.3 million, both up sharply, driven mainly by lower investments in working capital. Orders declined 4% to $825.5 million, with organic orders down 10%. The key concern is the Health & Science Technologies (HST) segment, where customers indicated a larger and more prolonged inventory correction than previously communicated. HST organic sales grew 3%, but its adjusted EBITDA margin fell 300 basis points to 28.7%, and management now expects HST's 2023 revenue growth to be negative. In response, management lowered full-year 2023 adjusted EPS guidance to $8.25 to $8.55 per share from $8.50 to $8.80 previously, while reported EPS guidance is $7.30 to $7.60 and full-year organic sales growth is projected at 0 to 3 percent. IDEX also announced an agreement in April 2023 to acquire Iridian Spectral Technologies for 150 million Canadian dollars, expected to close in the second quarter of 2023 subject to customary conditions. The guidance excludes this pending acquisition and all future acquisitions.
Idex Annual Report, Year Ended Dec 31, 2022
IDEX Corporation's 2022 Form 10-K reports a record year in sales, driven by robust demand, with net sales of $3,181.9 million, up 15% from $2,764.8 million in 2021. Organic sales rose 13%, and net income attributable to IDEX was $586.9 million, up 31%. Diluted EPS was $7.71, compared with $5.88 in 2021. Adjusted EBITDA reached $884.2 million, up 16%, with an Adjusted EBITDA margin of 27.9%. Management attributes the results to price capture amid inflation, execution, and the acquisition of Nexsight, KZValve and Muon Group during 2022. Cash flow from operations was $557.4 million, down from $565.3 million, as higher earnings were more than offset by increased working capital investment. Free cash flow was $489.4 million, or 79.2% of adjusted net income attributable to IDEX. Cash and cash equivalents fell to $430.2 million, and total borrowings rose to $1,477.8 million. The company repurchased 795,423 shares for $148.1 million and paid $177.4 million in dividends. Investing outflows of $917.2 million reflected acquisitions, including Muon Group for $713.0 million in cash. The Company stated it expects to refinance or repay its $100.0 million 3.20% Senior Notes due June 2023 using Revolving Facility capacity, and it reports a net available revolver borrowing capacity of $714.4 million. For 2023, management's stated priorities are foundational execution, building global teams, and capital deployment, with $1.5 billion deployed over the last two years on growth opportunities and a stated expectation of a high-quality acquisition pipeline. Credit ratings are BBB (S&P), Baa2 (Moody's) and BBB+ (Fitch), and the company reports compliance with its financial covenants.